Mounjaro (tirzepatide) in the UK: uses, access and safety

What Mounjaro does

Tirzepatide acts on two hormone receptors, called GIP and GLP-1 receptors. These pathways help control appetite and blood glucose. Many people feel satisfied after smaller meals. The medicine does more than make eating unpleasant. Persistent nausea, being unable to eat or dehydration are treatment problems to raise with your prescriber, and they do not signal a better result.

You inject the medicine under the skin. The UK KwikPen holds four prescribed weekly doses. The strength on its label is the dose per injection, and the pen holds more than one of those in total. Mounjaro pens do not swap with semaglutide pens, and milligrams do not compare directly between different medicines.

Who the UK licence covers

For weight management, Mounjaro is licensed for adults whose starting BMI is at least 30, or at least 27 with a weight-related health condition. The licence covers both losing weight and keeping weight off, alongside diet and activity support. You do not become unsuitable simply because treatment has brought your BMI below the starting threshold.

The September 2026 UK product information also covers treatment of insufficiently controlled type 2 diabetes from age 10. Weight-loss prescribing for children remains unapproved. Diabetes treatment in children and young people has its own specialist assessment and dose limits. Our weight-management information covers adults unless we say otherwise.

Licence, NHS funding and personal suitability

A licence sets out approved uses. NHS funding is a separate matter, and meeting a BMI threshold does not mean the medicine suits you. NHS access in England follows NICE recommendations and a phased commissioning programme. Scotland, Wales and Northern Ireland have their own pathways. Private treatment still needs a proper clinical assessment, a prescription and monitoring.

The assessment should cover other medicines, pregnancy plans, previous pancreatitis, significant digestive disease, diabetes complications and whether you can get continuing care. Discuss costs, follow-up and a practical plan for treatment becoming unaffordable before the first prescription.

Benefits in context

Clinical trials show large average weight reduction and better glucose control in suitable groups of people. Trial averages cannot predict your result. People differ in starting health, how well they tolerate doses, time on treatment, adherence and support. Some stop because of side effects or limited benefit. Comparing headline percentages from unrelated studies hides these differences.

Weight is one outcome. A good review also asks about food intake, physical function, blood pressure, glucose where relevant, quality of life and the burden of treatment. More weight loss is not always the right next goal.

Safety information to keep to hand

Read the leaflet supplied with your own device. UK labelling changes, and American articles often describe other brands, devices or warnings. Use this information to prepare for a talk with your clinician. Your prescription comes from that clinician.